She has been treated with leuprorelin 50 μg/kg every 4 weeks for 2 years, and her pubertal signs have not progressed, indicating that leuprorelin treatment is effective for this female Japanese patient with CPP caused by an MKRN3 mutation. The gene discussed is MKRN3; the disease is central precocious puberty.